Harbour BioMed Reports Full Year 2024 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...
PR Newswire21d
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...
vietreader.com1mon
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 26, 2025 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142 ...
PR Newswire1mon
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, ...
Mena FN1mon
Harbour Biomed Receives NMPA IND Clearance For HBM9378/SKB378 In The Treatment Of Chronic Obstructive Pulmonary Disease
HBM9378/SKB378 is designed to inhibit the TSLP-mediated signaling pathway, aiming to reduce airway inflammation and improve lung function in patients with COPD. "This regulatory clearance from the ...
manilatimes2mon
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
"We are delighted to partner with Windward Bio to advance the development of HBM9378/SKB378, a promising TSLP-targeted fully human antibody with significant potential to address immunological diseases ...
news-graphic2y
54 years of council experience leaves city hall
Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.